News Release

Printer Friendly Version View printer-friendly version
<< Back
Cell Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Rule

SEATTLE, Sept. 19, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced that it has received a letter from The NASDAQ Stock Market LLC (the "NASDAQ"), indicating that CTI has regained compliance with the minimum bid price rule (NASDAQ Listing Rule 5550(a)(2)) .

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit

Sign up for email alerts and get RSS feeds at our Web site,

Media Contact:

Dan Eramian
T: 206.272.4343
C: 206.854.1200

Investors Contact:

Ed Bell
T: 206.282.7100
F: 206.272.4434

SOURCE Cell Therapeutics, Inc.